Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Crohn’s Disease (Regiol Enteritis) - Overview
Crohn’s Disease (Regiol Enteritis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Crohn’s Disease (Regiol Enteritis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Crohn’s Disease (Regiol Enteritis) - Companies Involved in Therapeutics Development
Crohn’s Disease (Regiol Enteritis) - Drug Profiles
Crohn’s Disease (Regiol Enteritis) - Dormant Projects
Crohn’s Disease (Regiol Enteritis) - Discontinued Products
Crohn’s Disease (Regiol Enteritis) - Product Development Milestones
Featured News & Press Releases
Apr 19, 2022: People with moderate to severe uncontrolled Crohn’s disease granted early access to new investigatiol treatment in the UK
Apr 04, 2022: Thetis Pharmaceuticals secures $4.2 million from the Helmsley Charitable Trust to advance its first-in-class Resolvin oral therapy for Crohn’s Disease
Mar 30, 2022: Redx nomites GI-targeted ROCK inhibitor, RXC008, as clinical development candidate
Mar 28, 2022: Tizia commences Phase Ib trial of Crohn’s disease antibody
Mar 24, 2022: Celltrion Healthcare wins tender to supply Remsimato the Brazilian Federal Government
Feb 28, 2022: AbbVie provides update regarding SKYRIZI (risankizumab-rzaa) for the treatment of moderate to severe Crohn’s disease in the U.S.
Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn’s disease
Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn’s disease
Feb 20, 2022: Rapid improvement and remission in patients with refractory ulcerative colitis and crohn’s colitis after direct injection of Remestemcel-L by colonoscopy
Feb 18, 2022: The majority of adults with moderately to severely active Crohn’s disease in a phase 2 study achieved clinical remission and corticosteroid-free remission through 48 weeks with TREMFYA (guselkumab)
Feb 15, 2022: Statera Biopharma announces Central Institutiol Review Board approval of phase 3 clinical trial for pediatric Crohn’s disease
Feb 04, 2022: Tizia announces submission of amendment to Investigatiol New Drug Application to advance oral foralumab, a fully human anti-CD3 monoclol antibody, in patients with crohn’s disease
Feb 04, 2022: Mitsubishi Tabe’s 9 month sales rise fueled by strong growth in Stelara
Jan 06, 2022: Avalo reports positive phase 1b results for AVTX-002 in moderate to severe Crohn’s disease patients and Presents Additiol Program Updates at 2022 Investor Event
Dec 29, 2021: Statera Biopharma submits phase 3 clinical trial protocol to FDA for investigatiol treatment of pediatric Crohn’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Crohn’s Disease (Regional Enteritis), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Crohn’s Disease (Regional Enteritis), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Crohn’s Disease (Regional Enteritis) - Dormant Projects, 2022
Crohn’s Disease (Regional Enteritis) - Discontinued Products, 2022
Crohn’s Disease (Regional Enteritis) - Discontinued Products, 2022 (Contd..1)